A review of guidelines for use of growth hormone in pediatric and transition patients
- 24 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 15 (3), 301-310
- https://doi.org/10.1007/s11102-011-0372-6
Abstract
Growth hormone (GH) is approved by the US Food and Drug Administration (FDA) for use in pediatric patients with disorders of growth failure or short stature and in adults with growth hormone deficiency (GHD) and HIV/AIDS wasting and cachexia. For pediatric patients, guidelines for the use of GH have been developed by several organizations that have identified specific criteria for initiating GH therapy for each FDA-approved indication. Guidelines for adults have also been developed and include recommendations for transition (adolescent) patients with GHD. These patients are often treated with GH as children but may require continued treatment as young adults to attain full skeletal mineralization and improve cardiovascular risk factors. Adult and pediatric guidelines are supported by efficacy and safety studies, which show that, when started at an early age, GH treatment can increase growth velocity and that GH is safe and well-tolerated. We summarize the guidelines that are available for all FDA-approved indications among pediatric and transition patients. Adherence to these guidelines will help to ensure that patients with disorders of growth failure or short stature receive the necessary therapy to increase linear growth and transition smoothly to healthy adulthood.Keywords
This publication has 62 references indexed in Scilit:
- Safety of Recombinant Human Growth HormonePublished by S. Karger AG ,2010
- Health-Related Quality of Life of Children and Adolescents with Growth Hormone Deficiency or Idiopathic Short Stature – Part 2: Available Results and Future DirectionsHormone Research in Paediatrics, 2009
- Re-assessment of growth hormone secretion in young adult patients with childhood-onset growth hormone deficiencyClinical Endocrinology, 2003
- Growth hormone therapyBest Practice & Research Clinical Endocrinology & Metabolism, 2002
- The Cardiovascular Risk of GH-Deficient AdolescentsJournal of Clinical Endocrinology & Metabolism, 2002
- Cardiac Mass and Function, Carotid Artery Intima-Media Thickness, and Lipoprotein Levels in Growth Hormone-Deficient AdolescentsJournal of Clinical Endocrinology & Metabolism, 2001
- High Dose Recombinant Human Growth Hormone (GH) Treatment of GH-Deficient Patients in Puberty Increases Near-Final Height: A Randomized, Multicenter TrialJournal of Clinical Endocrinology & Metabolism, 2000
- Five years of growth hormone treatment in children with Prader‐Willi syndromeActa Paediatrica, 1999
- Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control SubjectsJournal of Clinical Endocrinology & Metabolism, 1999
- Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine SocietyaThe Journal of Pediatrics, 1995